Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients-Reference-Cited by-同舟云学术

Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients

Published:2016-11-03 Issue:11 Volume:11 Page:e0165658
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Zhang Yu,Cao Ying,Zhang Renwen,Zhang Xiaxia,Lu Haiying,Wu Chihong,Huo Na,Xu Xiaoyuan

Funder

the 12th Five-Year Plan of the National Major Project for Infectious Diseases Control

National Natural Science Foundation of China(CN)

Beijing Municipal Science and Technology Commission of major projects

the Postdoctoral Programs Foundation of China

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference29 articles.

1. Geneva WHO. Guidelines for the Screening, Care and Treatment of Persons with Hepatitis C Infection. 2014.http://www.ncbi.nlm.nih.gov/books/NBK263483/.

2. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection;H Rao;J Gastroenterol Hepatol,2014

3. Hepatitis C virus genotype and subtype distribution in Chinese chronic hepatitis C patients: nationwide spread of HCV genotypes 3 and 6;W Ju;VIROL J,2015

4. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study;M Manns;LANCET,2014

5. Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naive patients infected with HCV genotype 1 in Tunisia;JA Larousse;VIROL J,2015

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevalence and molecular genetic characteristics of parenteral hepatitis B, C and D viruses in HIV positive persons in the Novosibirsk region;Problems of Virology;2022-11-19

2. World-wide Prevalence of Substitutions in HCV Genome Associated With Resistance to Direct-Acting Antiviral Agents;Clinical Gastroenterology and Hepatology;2021-09

3. Efficacy and Safety of All-oral, 12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naïve Noncirrhotic HCV Genotype 1 Patients: Results from a Phase 2/3 Clinical Trial in China;Journal of Clinical and Translational Hepatology;2019-09-28

4. miR-27b-mediated suppression of aquaporin-11 expression in hepatocytes reduces HCV genomic RNA levels but not viral titers;Virology Journal;2019-05-02

5. Subtype-Specific Prevalence of Hepatitis C Virus NS5A Resistance Associated Substitutions in Mainland China;Frontiers in Microbiology;2019-03-19